Our findings suggested that the role of c-Myc in SCLC-N cells as a key modulator for immune characteristics and immunotherapy should be noted; compared with c-Myc, HDAC3 might be a better target for SCLC immunotherapy. This evidence concerns the gene MYC and small cell lung carcinoma.